736 related articles for article (PubMed ID: 10102291)
1. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
2. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
3. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
4. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
5. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
6. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Kwak HJ; Yang YS; Pae HO; Kim YM; Chung HT
Mol Cells; 2001 Oct; 12(2):178-84. PubMed ID: 11710518
[TBL] [Abstract][Full Text] [Related]
7. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
[TBL] [Abstract][Full Text] [Related]
8. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
[TBL] [Abstract][Full Text] [Related]
10. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12.
Yokoi H; Kato K; Kezuka T; Sakai J; Usui M; Yagita H; Okumura K
Eur J Immunol; 1997 Mar; 27(3):641-6. PubMed ID: 9079803
[TBL] [Abstract][Full Text] [Related]
11. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
12. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
[TBL] [Abstract][Full Text] [Related]
14. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis.
Suzuki J; Sakai J; Okada AA; Takada E; Usui M; Mizuguchi J
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):314-21. PubMed ID: 11981647
[TBL] [Abstract][Full Text] [Related]
16. Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.
Keino H; Takeuchi M; Usui Y; Hattori T; Yamakawa N; Kezuka T; Sakai JI; Usui M
Br J Ophthalmol; 2007 Jan; 91(1):105-10. PubMed ID: 16943228
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.
Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S
Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946
[TBL] [Abstract][Full Text] [Related]
18. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.
Xu H; Rizzo LV; Silver PB; Caspi RR
Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700
[TBL] [Abstract][Full Text] [Related]
19. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody.
Zhang R; Qian J; Guo J; Yuan YF; Xue K
Curr Eye Res; 2009 Apr; 34(4):297-303. PubMed ID: 19373578
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis.
Agarwal RK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1999 Mar; 162(5):2648-54. PubMed ID: 10072507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
